Evaluation of a Stepped Care Approach to Manage Depression in Diabetes (Ecce_homo)
Primary Purpose
Major Depressive Disorder, Minor Depressive Disorder, Sub-Threshold Depression
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Step 1: Diabetes-Specific CBT (5 group sessions)
Step 2: Depression-Specific CBT (6 single sessions)
Step 3: Referral to Psychotherapist and/or Psychiatrist
Standard Diabetes Education
Sponsored by
About this trial
This is an interventional treatment trial for Major Depressive Disorder focused on measuring Major Depression, Minor Depression, Sub-Threshold Depression, Affective Condition, Mood Disorder, Light Affective Disorder, Subclinical Depressive Symptoms, Diabetes Mellitus, Diabetes-Related Distress, Self-Care Behaviour, Glycaemic Control, Inflammatory Markers
Eligibility Criteria
Inclusion Criteria:
- Age >=18 and <=70
- Diabetes mellitus
- Elevated depressive symptoms (CES-D score >=16) and/or elevated diabetes-related distress (PAID score >=40)
- Sufficient language skills (German)
- Written informed consent
Exclusion Criteria:
- Severe depressive episode (F32.2/ F32.3)
- Current psychotherapeutic/ psychiatric treatment
- Current antidepressive medication
- Suicidal intention
- Current schizophrenia/ psychotic disorder, specified eating disorder, bipolar disorder, addictive disorder, personality disorder
- Severe physical illness (i.e. cancer, multiple sclerosis, dementia)
- Terminal illness
- Bedriddenness
- Guardianship
Sites / Locations
- Forschungsinstitut der Diabetes Akademie Mergentheim e. V.
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Stepped Care Approach for Depression
Treatment-as-usual
Arm Description
Step 1: Diabetes-Specific CBT (5 group sessions) Step 2: Depression-Specific CBT (6 single sessions) Step 3: Referral to Psychotherapist and/or Psychiatrist
Standard Diabetes Education
Outcomes
Primary Outcome Measures
Depressive Mood - Hamilton Rating Scale for Depression (HAMD)
Mean difference between HAMD scores at baseline and at 12 month follow up
Secondary Outcome Measures
Diabetes-Related Distress - The Problem Areas in Diabetes Questionnaire (PAID)
Mean difference between PAID scores at baseline and at 12 month follow up
Psychological/ Emotional Well-Being - The WHO-5 Well-being Index (WHO-5)
Mean difference between WHO-5 scores at baseline and at 12 month follow up
Health-Related Quality of Life - The Short Form-36 Health Survey (SF-36)
Mean difference between SF-36 scores at baseline and at 12 month follow up
Diabetes Self-Care Behavior - The Summary of Diabetes Self-Care Activities Measure (SDSCA)
Mean differences between SDSCA scores at baseline and at 12 month follow
Glycaemic Control (HbA1c)
Mean differences between HbA1c values at baseline and at 12 month follow
Health-Related Quality of Life - The EuroQol-5D (EQ-5D)
Mean differences between EQ-5D scores at baseline and at 12 month follow
Diabetes Self-Care Behavior - The Diabetes Self-Management Questionnaire (DSMQ)
Mean differences between DSMQ scores at baseline and at 12 month follow
Full Information
NCT ID
NCT01812291
First Posted
March 14, 2013
Last Updated
September 9, 2022
Sponsor
Forschungsinstitut der Diabetes Akademie Mergentheim
Collaborators
German Federal Ministry of Education and Research, German Diabetes Center, Heinrich-Heine University, Duesseldorf, University of Giessen, Helmholtz Zentrum München, Coordination Center for Clinical Trials (KKS)
1. Study Identification
Unique Protocol Identification Number
NCT01812291
Brief Title
Evaluation of a Stepped Care Approach to Manage Depression in Diabetes
Acronym
Ecce_homo
Official Title
Efficacy of a Stepped Care Approach to Manage Depression in Diabetic Patients and Putative Inflammatory Mechanisms Between Diabetes and Depression
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
November 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Forschungsinstitut der Diabetes Akademie Mergentheim
Collaborators
German Federal Ministry of Education and Research, German Diabetes Center, Heinrich-Heine University, Duesseldorf, University of Giessen, Helmholtz Zentrum München, Coordination Center for Clinical Trials (KKS)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The study examines the efficacy of a stepped care approach for depressed diabetes patients (first study objective). 256 patients with diabetes and comorbid subthreshold or clinical depression will be randomly assigned to either a stepped care approach or a treatment-as-usual condition. The stepped care approach consists of three treatment steps comprising diabetes-specific cognitive-behavioral therapy (CBT) (group), depression-specific CBT (single), and psychotherapeutic and/or psychiatric treatment (single). Patients assigned to the stepped care approach will be treated stepwise until a clinically significant reduction of depressive symptoms is attained or all three treatment steps are passed.
The primary outcome of the first study objective is a clinically significant reduction of depressive symptoms in the 12-month follow-up. Secondary outcomes are reduction of diabetes-related distress and improvement of well-being, health-related quality of life, diabetes acceptance, diabetes self-care, and glycaemic control. Additionally, cost-benefit analyses will be performed.
The second study objective is to analyse associations between diabetes, depression, and the serum levels of inflammatory markers.
The third study objective is to analyse the courses of depressive conditions in diabetes with regard to recovery rates and incidence of major depression.
Detailed Description
Compared to persons without diabetes, rates of depressive disorders and mood are doubled in diabetes patients. Epidemiologic studies have shown point prevalence rates of 10 - 14% for major depressive disorder and an additional proportion of almost 20% with subthreshold depression (defined as elevated depressive symptoms without meeting criteria for a specified clinical disorder). Depression and subthreshold depression in diabetes are associated with reduced quality of life, increased diabetes-related distress, and elevated health care costs. Furthermore, depression as well as subthreshold depression seem to be major barriers to an effective self-management of the disease and have been associated with reduced glycaemic control and hyperglycaemia. Both conditions seem to be independent prognostic factors for subsequent morbidity and mortality in diabetes.
Depressive conditions are commonly treated with psychotherapeutic or pharmacologic antidepressive therapies. Since the majority of diabetes patients is suffering from subthreshold depression, evaluated and suitable specific intervention concepts are rare. Moreover, the large variation of symptom levels of depressive patient groups suggests that different types of treatment with different treatment intensities may be required to match individual demands. The issue of 'optimal' treatment also regards concerns about overtreatment and undertreatment of particular patient groups with depressive conditions. Thus, an successive order of treatment steps of increasing intensity appears useful. Since depression in diabetes often is associated with high diabetes-related problems and distress, diabetes-specific as well as depression-specific interventions may be required.
We developed a stepped care approach with three treatment steps comprising diabetes-specific CBT (group), depression-specific CBT (single), and psychotherapeutic and/or psychiatric treatment (single).
The study is a randomized efficacy trial in which the efficacy of the stepped care approach is compared to a treatment-as-usual condition (standard diabetes education). 256 patients with diabetes and comorbid subthreshold or clinical depression will be randomly assigned to either the stepped care approach or the treatment-as-usual condition. Patients assigned to the stepped care approach will be treated stepwise until a clinically significant reduction of depressive symptoms is attained or all three treatment steps are passed.
The primary outcome is a clinically significant reduction of depressive symptoms in the 12-month follow-up. Secondary outcomes are reduction of diabetes-related distress and improvement of well-being, health-related quality of life, diabetes acceptance, diabetes self-care, and glycaemic control. The decisive measurement of this outcomes are conducted 12 months after the treatment (12 month follow up). Additionally, cost-benefit analyses will be performed.
Besides testing the efficacy of the stepped care approach (first objective), there are two additional study objectives:
The second study objective is to analyse associations between diabetes, depression, and the serum levels of inflammatory markers (C-reactive protein (CRP), Interleukin (IL)-6, IL-18, IL-1Ra, Adiponectin, Monocyte chemoattractant protein (MCP)-1). Additionally, the impact of depression treatment on the levels of these markers will be examined.
The third study objective is to analyse the courses of depressive conditions in diabetes with regard to recovery rates and incidence of major depression in subclinically or clinically depressed diabetes patients treated as usual vs. given an intervention.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder, Minor Depressive Disorder, Sub-Threshold Depression, Diabetes Mellitus
Keywords
Major Depression, Minor Depression, Sub-Threshold Depression, Affective Condition, Mood Disorder, Light Affective Disorder, Subclinical Depressive Symptoms, Diabetes Mellitus, Diabetes-Related Distress, Self-Care Behaviour, Glycaemic Control, Inflammatory Markers
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
260 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Stepped Care Approach for Depression
Arm Type
Experimental
Arm Description
Step 1: Diabetes-Specific CBT (5 group sessions)
Step 2: Depression-Specific CBT (6 single sessions)
Step 3: Referral to Psychotherapist and/or Psychiatrist
Arm Title
Treatment-as-usual
Arm Type
Active Comparator
Arm Description
Standard Diabetes Education
Intervention Type
Behavioral
Intervention Name(s)
Step 1: Diabetes-Specific CBT (5 group sessions)
Intervention Description
Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').
Includes:
Diabetes problem analysis/ definition
Diabetes problem solving intervention
Cognitive restructuring of diabetes problems
Activation of personal and social resources
Goal definition and agreement
Intervention Type
Behavioral
Intervention Name(s)
Step 2: Depression-Specific CBT (6 single sessions)
Intervention Description
Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).
Includes:
Functional explanatory model of depression
Cognitive restructuring of negative thoughts
Practice of alternative beneficial thoughts
Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity.
Intervention Type
Behavioral
Intervention Name(s)
Step 3: Referral to Psychotherapist and/or Psychiatrist
Intervention Description
Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
Intervention Type
Behavioral
Intervention Name(s)
Standard Diabetes Education
Intervention Description
Standard diabetes education and professional care.
Includes:
Health care and specific topics (e. g. blood pressure)
Diabetes complications
Healthy and unhealthy foods, cooking recommendations and recipes
Foot care: exercises, care and control, injuries, and diabetic neuropathy
Sports, activities and exercise
Social aspects of living with diabetes
Primary Outcome Measure Information:
Title
Depressive Mood - Hamilton Rating Scale for Depression (HAMD)
Description
Mean difference between HAMD scores at baseline and at 12 month follow up
Time Frame
12 month
Secondary Outcome Measure Information:
Title
Diabetes-Related Distress - The Problem Areas in Diabetes Questionnaire (PAID)
Description
Mean difference between PAID scores at baseline and at 12 month follow up
Time Frame
12 months
Title
Psychological/ Emotional Well-Being - The WHO-5 Well-being Index (WHO-5)
Description
Mean difference between WHO-5 scores at baseline and at 12 month follow up
Time Frame
12 month
Title
Health-Related Quality of Life - The Short Form-36 Health Survey (SF-36)
Description
Mean difference between SF-36 scores at baseline and at 12 month follow up
Time Frame
12 month
Title
Diabetes Self-Care Behavior - The Summary of Diabetes Self-Care Activities Measure (SDSCA)
Description
Mean differences between SDSCA scores at baseline and at 12 month follow
Time Frame
12 month
Title
Glycaemic Control (HbA1c)
Description
Mean differences between HbA1c values at baseline and at 12 month follow
Time Frame
12 month
Title
Health-Related Quality of Life - The EuroQol-5D (EQ-5D)
Description
Mean differences between EQ-5D scores at baseline and at 12 month follow
Time Frame
12 month
Title
Diabetes Self-Care Behavior - The Diabetes Self-Management Questionnaire (DSMQ)
Description
Mean differences between DSMQ scores at baseline and at 12 month follow
Time Frame
12 month
Other Pre-specified Outcome Measures:
Title
Inflammatory Markers
Description
Serum levels of the inflammatory markers CRP, IL-6, IL-18, IL-1Ra, Adiponectin, MCP-1 are assessed to enable analyses with regard to the second study objective - associations between diabetes, depression, and inflammation. The measurement of this additional outcome variable is conducted twice, at baseline and 12 months after the treatment (12 month follow up).
Time Frame
Baseline, 12 month follow up
Title
Major Depressive Disorder
Description
Difference in rates of major depression according to ICD-10 criteria between baseline and 12 months follow up
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age >=18 and <=70
Diabetes mellitus
Elevated depressive symptoms (CES-D score >=16) and/or elevated diabetes-related distress (PAID score >=40)
Sufficient language skills (German)
Written informed consent
Exclusion Criteria:
Severe depressive episode (F32.2/ F32.3)
Current psychotherapeutic/ psychiatric treatment
Current antidepressive medication
Suicidal intention
Current schizophrenia/ psychotic disorder, specified eating disorder, bipolar disorder, addictive disorder, personality disorder
Severe physical illness (i.e. cancer, multiple sclerosis, dementia)
Terminal illness
Bedriddenness
Guardianship
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bernhard Kulzer, PD Dr.
Organizational Affiliation
Forschungsinstitut der Diabetes Akademie Mergentheim
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Norbert Hermanns, Prof. Dr.
Organizational Affiliation
Forschungsinstitut der Diabetes Akademie Mergentheim
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Thomas Haak, Prof. Dr.
Organizational Affiliation
Forschungsinstitut der Diabetes Akademie Mergentheim
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Johannes Kruse, Prof. Dr.
Organizational Affiliation
University of Giessen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Forschungsinstitut der Diabetes Akademie Mergentheim e. V.
City
Bad Mergentheim
State/Province
Baden-Wuerttemberg
ZIP/Postal Code
D-97980
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
35526518
Citation
Schmitt A, Kulzer B, Ehrmann D, Haak T, Hermanns N. Diabetes Distress and Depression during COVID-19: Response to Breznoscakova et al. Uncovering the Untold Emotional Toll of Living with Diabetes in the COVID-19 Era. Psychother Psychosom. 2022;91(4):288-289. doi: 10.1159/000524602. Epub 2022 May 6. No abstract available.
Results Reference
background
PubMed Identifier
34875666
Citation
Schmitt A, Kulzer B, Reimer A, Herder C, Roden M, Haak T, Hermanns N. Evaluation of a Stepped Care Approach to Manage Depression and Diabetes Distress in Patients with Type 1 Diabetes and Type 2 Diabetes: Results of a Randomized Controlled Trial (ECCE HOMO Study). Psychother Psychosom. 2022;91(2):107-122. doi: 10.1159/000520319. Epub 2021 Dec 7.
Results Reference
result
PubMed Identifier
29520075
Citation
Herder C, Schmitt A, Budden F, Reimer A, Kulzer B, Roden M, Haak T, Hermanns N. Association between pro- and anti-inflammatory cytokines and depressive symptoms in patients with diabetes-potential differences by diabetes type and depression scores. Transl Psychiatry. 2018 Mar 9;7(11):1. doi: 10.1038/s41398-017-0009-2.
Results Reference
result
PubMed Identifier
29525039
Citation
Herder C, Schmitt A, Budden F, Reimer A, Kulzer B, Roden M, Haak T, Hermanns N. Longitudinal associations between biomarkers of inflammation and changes in depressive symptoms in patients with type 1 and type 2 diabetes. Psychoneuroendocrinology. 2018 May;91:216-225. doi: 10.1016/j.psyneuen.2018.02.032. Epub 2018 Mar 6.
Results Reference
result
PubMed Identifier
25047992
Citation
Schmitt A, Reimer A, Kulzer B, Haak T, Gahr A, Hermanns N. Assessment of diabetes acceptance can help identify patients with ineffective diabetes self-care and poor diabetes control. Diabet Med. 2014 Nov;31(11):1446-51. doi: 10.1111/dme.12553. Epub 2014 Aug 2.
Results Reference
derived
Learn more about this trial
Evaluation of a Stepped Care Approach to Manage Depression in Diabetes
We'll reach out to this number within 24 hrs